A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

Progress on Kinesin Spindle Protein Inhibitors as Anti-Cancer Agents

(2013) Yingjie Zhang et al.   Anti-Cancer Agents in Medicinal Chemistry

Kinesin motor proteins as targets for cancer therapy

(2009) Dennis Huszar et al.   CANCER AND METASTASIS REVIEWS

K858, a Novel Inhibitor of Mitotic Kinesin Eg5 and Antitumor Agent, Induces Cell Death in Cancer Cells

(2009) R. Nakai et al.   CANCER RESEARCH

Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor

(2008) Min Liu et al.   BIOCHEMICAL PHARMACOLOGY

Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes

(2008) Tomasz M. Beer et al.   Clinical Genitourinary Cancer

A University of Chicago Consortium Phase II Trial of SB-715992 in Advanced Renal Cell Cancer

(2008) Richard T. Lee et al.   Clinical Genitourinary Cancer

A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)

(2008) Jennifer J. Knox et al.   INVESTIGATIONAL NEW DRUGS

Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity

(2008) Norihiro Hayashi et al.   PROSTATE